Sandbox MKK: Difference between revisions
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
|BID | |BID | ||
|14 days | |14 days | ||
| | |YES(a) | ||
|- | |- | ||
|Bismuth Quadruple | |Bismuth Quadruple | ||
| Line 41: | Line 41: | ||
TID to QID (500mg) | TID to QID (500mg) | ||
|10-14 days | |10-14 days | ||
| | |NO | ||
|- | |- | ||
|Concomitant | |Concomitant | ||
| Line 52: | Line 52: | ||
|BID | |BID | ||
|10 -14 days | |10 -14 days | ||
| | |NO | ||
|- | |- | ||
|Sequential | |Sequential | ||
| Line 63: | Line 63: | ||
5-7 days | 5-7 days | ||
| | |NO | ||
|- | |- | ||
|Hybrid | |Hybrid | ||
| Line 72: | Line 72: | ||
|7 days | |7 days | ||
7 days | 7 days | ||
| | |NO | ||
|- | |- | ||
|Levofloxacin triple | |Levofloxacin triple | ||
| Line 85: | Line 85: | ||
|10-14 days | |10-14 days | ||
| | |NO | ||
|- | |- | ||
|Levofloxacin sequential | |Levofloxacin sequential | ||
| Line 93: | Line 93: | ||
BID | BID | ||
|5-7 days | |5-7 days | ||
| | |NO | ||
|- | |- | ||
|LOAD | |LOAD | ||
| Line 109: | Line 109: | ||
QD | QD | ||
|7-10 days | |7-10 days | ||
| | |NO | ||
|} | |} | ||
Revision as of 20:36, 26 October 2017
The ACG’s 2007 treatment guideline on the management of H. pylori infection (26) listed the following as established indications for diagnosis and treatment:
Active PUD (gastric or duodenal).
Confirmed history of PUD (not previously treated for H. pylori)
Gastric MALT lymphoma (low grade).
After endoscopic resection of EGC.
Recommenend first line treatment for Helicobacter pylori
| Regimen | Drug dose | Dosing frequency | Duration(days) | FDA approval |
|---|---|---|---|---|
| Clarithromycin triple | PPI(standard or double dose
Clarithromycin(500mg) Amoxicillin(1gm)or Metronidazole(500mg TID) |
BID | 14 days | YES(a) |
| Bismuth Quadruple | PPI(standard dose)
Bismuth subcitrate (120-300mg)or Subsalicylate (300mg) Tetracyclin(500mg) Metronidazole(250-500mg) |
BID
QID QID TID to QID (500mg) |
10-14 days | NO |
| Concomitant | PPI (standard dose)
Clarithromycin (500mg) Amoxicillin(1gm) Nitroimidazole(500mg) |
BID | 10 -14 days | NO |
| Sequential | PPI(standard dose)+Amoxicillin(1gm)
PPI,Clarithromycin(500mg)+Nitroimidazole(500mg) |
BID
BID |
5-7 days
5-7 days |
NO |
| Hybrid | PPI(standard)+Amoxicillin(1gm)
PPI,Amoxicillin,Clarithromycin(500mg),Nitroimidazole(500mg) |
BID
BID |
7 days
7 days |
NO |
| Levofloxacin triple | PPI(standard dose)
Levofloxacin(500mg) Amoxicillin(1gm) |
BID
QID BID |
10-14 days | NO |
| Levofloxacin sequential | PPI(standard or double dose)+Amoxicillin(1 gm)
PPI,Amoxicillin,Levofloxacin(500mg QD),Nitroimidazole(500mg) |
BID
BID |
5-7 days | NO |
| LOAD | Levofloxacin(250mg)
PPI(double dose) Nitazoxanide(500mg) Doxycycline(100mg) |
QD
QD BID QD |
7-10 days | NO |
Adjuvant therapy in the treatment of H. pylori infection. Emerging evidence suggests an inhibitory effect of Lactobacillus and Bifidobacterium species on H. pylori. Furthermore, these probiotic strains may also help to reduce the side effects of eradication therapies and improve compliance with therapy.
Firstline Treatment
Selection of a first-line H. pylori treatment regimen:
| •Is there a penicillin (PCN) allergy? •Previous macrolide (MCL) exposure for any reason ? | |||||||||||||||||||||||||||||||||||||
| •PCN allergy: No •MCL exposure: No | •PCN allergy: No •MCL exposure: Yes | •PCN allergy: Yes •MCL exposure: No | •PCN allergy: Yes •MCL exposure: Yes | ||||||||||||||||||||||||||||||||||
| Recomended treatment: •Bismuth quadruple •Clarithromycin triple with amoxicillin •Other options: •Sequential •HYBRID •Levofloxacin triple •Levofloxacin sequential •LOAD | Recomended treatment: •Bismuth quadruple •Levofloxacin sequential •Other options: •Concomitant therapy •Sequential therapy • HYBRID •LOAD | Recomended treatment: •Bismuth quadruple •Clarithromycin triple with metronidazole •Bismuth quadruple | Recomended treatment: •Bismuth quadruple •Clarithromycin triple with metronidazole •Bismuth quadruple | ||||||||||||||||||||||||||||||||||